Democratic presidential candidate Barack Obama’s health plan continues to hold a lead over the plan put forth by Republican John McCain in a survey being conducted at DiagnosticImaging.com.
Democratic presidential candidate Barack Obama's health plan continues to hold a lead over the plan put forth by Republican John McCain in a survey being conducted at DiagnosticImaging.com. As of Oct. 20, the survey had received 231 votes. Obama's plan was favored by 45% and McCain's by 40%. Another 6% favored a different plan, 6% favored no plan, and 3% were undecided. The survey was posted on Oct. 7 and is scheduled to run until the Nov. 4 election. The poll is an unscientific snapshot of site visitor opinion. Though prone to sampling bias, it is structured to prevent multiple votes from individual sources. Final results will be reported at DiagnosticImaging.com. A similar survey is appearing at CancerNetwork.com, a site run by two oncology publications under the same corporate banner as Diagnostic Imaging. A separate web poll being run by Epocrates found slightly higher support for the Obama plan, 47% to McCain's 30%, with 23% of respondents answering neither. As of Oct. 20, 1179 respondents had voted. That poll started Oct. 3.
Among the highlights of the Epocrates poll are the following findings:
For more information from the Diagnostic Imaging archives:
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.